NASDAQ:GRPH

Graphite Bio - GRPH Stock Forecast, Price & News

$3.43

-0.07 (-2.00%)

(As of 12/7/2022 12:00 AM ET)

Add

Compare

Today's Range: $3.35
▼
$3.58
50-Day Range: $3.06
▼
$3.61
52-Week Range: $2.07
▼
$13.39

Volume: 43,814 shs
Average Volume: 369,294 shs
Market Capitalization: $199.46 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.83

Graphite Bio MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 274.1% Upside
$12.83 Price Target
Short Interest: Healthy
4.71% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.00
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.85) to ($2.36) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.92 out of 5 stars

Medical Sector

691st out of 1,027 stocks

Biological Products, Except Diagnostic Industry

107th out of 171 stocks

3.3

Analyst's Opinion

Consensus Rating
Graphite Bio has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $12.83, Graphite Bio has a forecasted upside of 274.1% from its current price of $3.43.
Amount of Analyst Coverage
Graphite Bio has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
4.71% of the float of Graphite Bio has been sold short.
Short Interest Ratio / Days to Cover
Graphite Bio has a short interest ratio ("days to cover") of 6.8.
Change versus previous month
Short interest in Graphite Bio has recently decreased by 3.85%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Graphite Bio does not currently pay a dividend.
Dividend Growth
Graphite Bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GRPH.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 2 news articles for Graphite Bio this week, compared to 0 articles on an average week.
Search Interest
2 people have searched for GRPH on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Graphite Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Graphite Bio insiders have not sold or bought any company stock.
Percentage Held by Insiders
38.45% of the stock of Graphite Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
51.83% of the stock of Graphite Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Graphite Bio are expected to decrease in the coming year, from ($1.85) to ($2.36) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Graphite Bio is -1.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Graphite Bio is -1.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Graphite Bio has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Graphite Bio (NASDAQ:GRPH) Stock

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Receive GRPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Graphite Bio and its competitors with MarketBeat's FREE daily newsletter.

GRPH Stock News Headlines

December 2, 2022 | americanbankingnews.com

Analysts Set Graphite Bio, Inc. (NASDAQ:GRPH) Price Target at $11.80

November 21, 2022 | finance.yahoo.com

Graphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx Conference

November 9, 2022 | finance.yahoo.com

Graphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial Results

November 5, 2022 | barrons.com

Graphite Bio Announces Abstracts Accepted for Upcoming 64(th) ASH Annual Meeting and Exposition

November 3, 2022 | finance.yahoo.com

Graphite Bio Announces Abstracts Accepted for Upcoming 64th ASH Annual Meeting and Exposition

October 16, 2022 | finance.yahoo.com

Here's Why We're Watching Graphite Bio's (NASDAQ:GRPH) Cash Burn Situation

October 11, 2022 | finance.yahoo.com

Graphite Bio Announces Participation in 50th Annual Sickle Cell Disease Association of America National Convention

September 21, 2022 | seekingalpha.com

GRPH Graphite Bio, Inc.

September 6, 2022 | finance.yahoo.com

Graphite Bio Announces Participation in Morgan Stanley 20th Annual Global Healthcare Conference

August 30, 2022 | finance.yahoo.com

Potential sickle cell disease 'cure' jumps to clinic, yet investors remain cool

August 12, 2022 | msn.com

Graphite Bio Shares Soar As Initial-Stage Blood Cell Disorder Study Launched

August 11, 2022 | finance.yahoo.com

Graphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease

August 11, 2022 | finance.yahoo.com

Graphite Bio Reports Recent Business Progress and Second Quarter 2022 Financial Results

July 7, 2022 | barrons.com

Graphite Bio Inc.

June 17, 2022 | markets.businessinsider.com

Where Graphite Bio Stands With Analysts

June 17, 2022 | finance.yahoo.com

BMO Capital Sees Over 400% Upside For This Small Gene-Editing Stock

June 1, 2022 | finance.yahoo.com

Graphite Bio Announces Participation in Jefferies Healthcare Conference

May 29, 2022 | finance.yahoo.com

I'm 'Following Up' on a Biotech Trade With Attractive Potential

May 25, 2022 | seekingalpha.com

Graphite Bio: Selling For Much Less Than Net Cash

May 16, 2022 | finance.yahoo.com

Graphite Bio Presents Preclinical Gene Replacement Data for GPH102 for Beta-thalassemia at the ASGCT 25th Annual Meeting

May 13, 2022 | markets.businessinsider.com

Analyst Ratings for Graphite Bio

May 13, 2022 | finance.yahoo.com

Graphite Bio Reports Recent Business Progress and First Quarter 2022 Financial Results

May 3, 2022 | finance.yahoo.com

Graphite Bio Announces U.S. FDA Fast Track Designation Granted to GPH101 for the Treatment of Sickle Cell Disease

May 2, 2022 | finance.yahoo.com

Graphite Bio Announces Participation in the ASGCT 25th Annual Meeting Including Oral Presentation About Beta-thalassemia Program

April 14, 2022 | markets.businessinsider.com

What 4 Analyst Ratings Have To Say About Graphite Bio

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive GRPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Graphite Bio and its competitors with MarketBeat's FREE daily newsletter.

GRPH Company Calendar

Last Earnings: 11/09/2022
Today: 12/07/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/20/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GRPH
CUSIP: N/A
CIK: 1815776
Web: www.graphitebio.com
Phone: 650-484-0886
Fax: N/A
Employees: 69
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $12.83
High Stock Price Forecast: $18.00
Low Stock Price Forecast: $6.00
Forecasted Upside/Downside: +274.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.76)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-70,760,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -27.25%
Return on Assets: -25.97%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 22.07
Quick Ratio: 22.07

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.61 per share
Price / Book: 0.52

Miscellaneous

Outstanding Shares: 58,152,000
Free Float: 35,793,000
Market Cap: $199.46 million
Optionable: Not Optionable
Beta: 0.44

Key Executives

Dr. Joshua Lehrer-Graiwer FACC (Age 48)
M.D., Pres, CEO & Director
Comp: $724.58k

Dr. Matthew Porteus M.D. (Age 57)
Ph.D., Academic Founder & Director
Comp: $90.77k

Dr. Maria Grazia Roncarolo M.D. (Age 68)
Ph.D., Academic Founder & Chair of Scientific Advisory Board
Comp: $70k

Mr. Philip P. Gutry (Age 49)
Chief Bus. Officer
Comp: $541.33k

Dr. Daniel Dever Ph.D.
Co-Founder & Head of Discovery Research

Ms. Alethia Rene Young (Age 43)
Chief Financial Officer

Dr. Christine Garrett P.M.P. (Age 51)
Ph.D., Chief of Staff & Sr. VP of Operations

Mr. Jerry Cacia (Age 55)
Chief Technical Officer

Dr. Jane Grogan Ph.D. (Age 54)
Chief Scientific Officer

Stephanie Yao
VP of Communications & Investor Relations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GRPH Stock - Frequently Asked Questions

Should I buy or sell Graphite Bio stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Graphite Bio in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GRPH shares.
View GRPH analyst ratings or view top-rated stocks.
What is Graphite Bio's stock price forecast for 2023?: 6 Wall Street analysts have issued 12-month price objectives for Graphite Bio's shares. Their GRPH share price forecasts range from $6.00 to $18.00. On average, they anticipate the company's share price to reach $12.83 in the next twelve months. This suggests a possible upside of 274.1% from the stock's current price.
View analysts price targets for GRPH or view top-rated stocks among Wall Street analysts.
How have GRPH shares performed in 2022?: Graphite Bio's stock was trading at $12.43 at the beginning of the year. Since then, GRPH shares have decreased by 72.4% and is now trading at $3.43.
View the best growth stocks for 2022 here.
When is Graphite Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 20th 2023.
View our GRPH earnings forecast.
How were Graphite Bio's earnings last quarter?: Graphite Bio, Inc. (NASDAQ:GRPH) issued its quarterly earnings results on Wednesday, November, 9th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.04.

When did Graphite Bio IPO?: (GRPH) raised $224 million in an initial public offering on Friday, June 25th 2021. The company issued 14,000,000 shares at $15.00-$17.00 per share.
What is Graphite Bio's stock symbol?: Graphite Bio trades on the NASDAQ under the ticker symbol "GRPH."
Who are Graphite Bio's major shareholders?: Graphite Bio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include EcoR1 Capital LLC (2.72%), Vanguard Group Inc. (2.06%), Privium Fund Management UK Ltd (0.97%), Renaissance Technologies LLC (0.90%), BlackRock Inc. (0.83%) and Prosight Management LP (0.61%). Insiders that own company stock include Biocapital LP Samsara and Phil Gutry.
View institutional ownership trends.
How do I buy shares of Graphite Bio?: Shares of GRPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Graphite Bio's stock price today?: One share of GRPH stock can currently be purchased for approximately $3.43.
How much money does Graphite Bio make?: Graphite Bio (NASDAQ:GRPH) has a market capitalization of $199.46 million. The company earns $-70,760,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis.
How can I contact Graphite Bio?: The official website for the company is www.graphitebio.com. The company can be reached via phone at 650-484-0886 or via email at ir@graphitebio.com.

This page (NASDAQ:GRPH) was last updated on 12/8/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial